Clavulanic acid
- Generic Name
- Clavulanic acid
- Brand Names
- Clavulin, Augmentin
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9NO5
- CAS Number
- 58001-44-8
- Unique Ingredient Identifier
- 23521W1S24
- Background
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus.When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.
- Indication
Clavulanic acid combined with other antibiotics is indicated to prevent the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.
The following conditions, when they produced beta-lactamases, have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acid:
Acute otitis media caused by H. influenzae and M. catarrhalis
Sinusitis due to H. influenzae and M. catarrhalis
Lower respiratory tract infections due to Haemophilus influenzae, S.aureus, Klebsiella species, and Moraxella catarrhalis
Skin and skin structure infections caused by Staphylococcus aureus, Escherichia coli, and Klebsiella species
Urinary Tract Infections due to E. coli, Klebsiella species of bacteria, and Enterobacter species of bacteria, S.marcescens, or S.aureus
Gynecologic infections due to a variety of bacteria, including P.melaninogenicus, Enterobacter species, E.Coli species, Klebsiella species, S. aureus, S.epidermidis
Septicemia due to a variety of bacteria, including Klebsiella species, E.Coli species, S.aureus, or Pseudomonas species
Bone and joint infections due to S.aureus
Intraabdominal infections due to E.Coli, K.pnemoniae, or B.fragilis group
A note on susceptibility
It should be noted that it is only to be administered in infections that are confirmed or highly likely to be caused by susceptible bacteria. Culture and susceptibility tests should be performed if possible and used in selecting whether this antibiotic is prescribed. When beta-lactamase enzyme production is not detected during microbiological testing, clavulanic acid should not be used. When these tests are not available patterns of local infection and susceptibility may be used to determine the appropriateness of using clavulanic acid. Ticarcillin with clavulanate has shown particular efficacy in mixed infections in addition to empiric therapy before determining the susceptibility of causative organisms. The ticarcillin-clavulanic acid combination may prove to be an effective single-agent antibiotic therapy to treat infections where a regimen of several drugs may normally be used.
- Associated Conditions
- Infection Due to Escherichia Coli, Skin and skin structure infections, Acute Uncomplicated Pyelonephritis, Bronchitis, Haemophilus Influenzae, Lower Respiratory Infection, Otitis Media (OM), Moraxella catarrhalis, Upper Respiratory Tract Infection, Acute Cystitis, Cysto-Urethritis, Bone and Joint Infections, Sinusitis, Intraabdominal Infections, Tonsillitis, Proteus mirabilis, Lower Respiratory Tract Infection (LRTI), Neisseria Gonorrhoeae Infection, Susceptible Bacterial Infections, Pharyngitis, Bacterial infection due to streptococcus, group A, Urinary Tract Infection, Septicemia, Bacterial Infections, Bacterial Pneumonia, Streptococcus Pneumoniae, Gynecological Infection
Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost
• Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.
• Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet.
• The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.
FDA Approves Orlynvah, a New Oral Penem Antibiotic, for Uncomplicated UTIs
• The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) as the first oral penem antibiotic for uncomplicated urinary tract infections (uUTIs).
• Orlynvah is indicated for adult women with uUTIs caused by specific bacteria, including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, when other oral options are limited.
• Clinical trials demonstrated Orlynvah's superiority over ciprofloxacin in fluoroquinolone-resistant infections and statistical superiority to Augmentin in Augmentin-susceptible cases.
• Orlynvah offers a new treatment option to combat antimicrobial resistance, particularly in quinolone-resistant organisms and ESBL-producing E. coli, potentially reducing hospitalizations.
Iterum's Orlynvah Approved for UTIs Following Positive SURE1 and REASSURE Trial Results
• Orlynvah (sulopenem), developed by Iterum Therapeutics, gains FDA approval for uncomplicated urinary tract infections (uUTIs) after successful SURE1 and REASSURE trials.
• The SURE1 trial showed Orlynvah's superiority over ciprofloxacin in infections caused by ciprofloxacin-resistant organisms but did not demonstrate non-inferiority in susceptible organisms.
• The REASSURE trial confirmed Orlynvah's superiority in susceptible populations and established non-inferiority across the overall population compared to augmentin.
• Iterum Therapeutics is now seeking a strategic partner to effectively launch Orlynvah, targeting primary care physicians, urologists, and OB-GYNs.
Iterum's Orlynvah Receives FDA Approval for Uncomplicated Urinary Tract Infections
• The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
• Approval was based on Phase 3 trials SURE 1 and REASSURE, demonstrating superiority to ciprofloxacin and non-inferiority/superiority to Augmentin, respectively.
• Orlynvah is the first approved indication for Iterum Therapeutics and the first oral penem available in the U.S. for uUTIs.
• This approval addresses the growing concern of antimicrobial resistance and provides a new treatment option for patients and physicians.
FDA Approves Iterum's ORLYNVAH for Uncomplicated Urinary Tract Infections
• The FDA has approved Iterum Therapeutics' ORLYNVAH (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women.
• ORLYNVAH is a novel oral penem antibiotic effective against Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, including strains resistant to third-generation cephalosporins.
• Clinical trials (SURE 1 and REASSURE) demonstrated ORLYNVAH's superiority to ciprofloxacin in fluoroquinolone-resistant infections and non-inferiority/superiority to Augmentin.
• Iterum aims to pursue a strategic transaction for ORLYNVAH to maximize stakeholder value, offering a new option to combat antimicrobial resistance in uUTI treatment.
FDA Approves Iterum's Orlynvah for Uncomplicated Urinary Tract Infections
• The FDA has approved Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) for treating adult women with uncomplicated urinary tract infections (uUTIs).
• Orlynvah, an oral penem antibiotic, targets infections caused by bacteria like Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, offering an alternative for those with limited options.
• The approval was based on Phase 3 trials (SURE 1 and REASSURE) demonstrating Orlynvah's safety and efficacy compared to ciprofloxacin and Augmentin, respectively.
• Iterum Therapeutics aims to commercially launch Orlynvah around mid-2025 and is seeking a strategic transaction to maximize its value.
Iterum's Oral Antibiotic Orlynvah Approved by FDA for Uncomplicated UTIs
• Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) has received FDA approval for treating uncomplicated urinary tract infections (uUTIs) in adult women.
• Orlynvah is the first oral penem antibiotic approved in the U.S., targeting key uUTI-causing microorganisms like _Escherichia coli_, _Klebsiella pneumoniae_, and _Proteus mirabilis_.
• The approval is supported by Phase III trials, including the REASSURE study demonstrating non-inferiority to Augmentin and superiority over ciprofloxacin in quinolone-resistant infections.
• Iterum plans to pursue a strategic transaction to commercialize Orlynvah, aiming to maximize stakeholder value and address antimicrobial resistance.
FDA Approves Oral Antibiotic Orlynvah for Uncomplicated UTIs
• The FDA has approved Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) in adult women.
• Orlynvah is the first oral penem antibiotic approved in the U.S., offering a new treatment option for infections caused by specific bacteria.
• Clinical trials demonstrated Orlynvah's efficacy compared to ciprofloxacin in fluoroquinolone-resistant infections and Augmentin in susceptible populations.
• Up to 60% of women experience a uUTI in their lifetime, highlighting the need for new treatments like Orlynvah.
FDA Approves Orlynvah for Uncomplicated Urinary Tract Infections in Women with Limited Oral Antibiotic Options
• The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
• Orlynvah, the first oral penem antibiotic approved in the U.S., targets uUTIs caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
• Clinical trials (SURE 1 and REASSURE) demonstrated Orlynvah's superiority to ciprofloxacin in fluoroquinolone-resistant infections and non-inferiority/superiority to Augmentin™.
• Orlynvah is administered orally twice daily for five days and is not indicated for complicated UTIs or intra-abdominal infections.
FDA Approves Iterum's Oral Penem ORLYNVAH™ for Uncomplicated Urinary Tract Infections
• The FDA has approved ORLYNVAH™ (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) in adult women with limited oral treatment options.
• ORLYNVAH™ is the first oral penem antibiotic approved in the U.S., offering a new treatment alternative for infections caused by specific resistant microorganisms.
• Clinical trials (SURE 1 and REASSURE) demonstrated ORLYNVAH™'s superiority to ciprofloxacin and non-inferiority/statistical superiority to Augmentin™ in susceptible populations.
• Iterum Therapeutics aims to pursue strategic transactions to maximize ORLYNVAH™'s value and address the unmet need in the uUTI market amidst rising antibiotic resistance.
Iterum's Oral Sulopenem Faces FDA Decision Amidst Antibiotic Resistance Concerns
• Iterum Therapeutics' oral sulopenem, an antibiotic for uncomplicated urinary tract infections (uUTIs), awaits an FDA decision by October 25.
• An FDA advisory committee acknowledged oral sulopenem as an important treatment option, particularly for multi-drug resistant pathogens.
• Concerns remain about potential misuse and the need for antibiotic stewardship to prevent further antimicrobial resistance.
• Post-marketing surveillance and clear labeling are crucial to ensure responsible prescription and limit off-label use of oral sulopenem.
FDA Accepts Resubmission of NDA for Oral Sulopenem in Uncomplicated UTIs
• The FDA has accepted Iterum Therapeutics' resubmitted New Drug Application (NDA) for oral sulopenem for treating uncomplicated urinary tract infections (uUTIs).
• The FDA has granted a Prescription Drug User Fee Act (PDUFA) action date of October 25, 2024, for oral sulopenem.
• The resubmission includes data from the REASSURE clinical trial, which demonstrated oral sulopenem's non-inferiority and statistically significant superiority compared to Augmentin®.
• Oral sulopenem, if approved, could provide a much-needed treatment option for adult women with uUTIs caused by multi-drug resistant pathogens.
Iterum Therapeutics Resubmits NDA for Oral Sulopenem to Treat Uncomplicated UTIs
• Iterum Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for oral sulopenem, targeting uncomplicated urinary tract infections (uUTIs) in adult women.
• The resubmission includes data from Phase 3 trials (REASSURE, SURE 1, SURE 2, SURE 3) demonstrating oral sulopenem's efficacy and safety compared to Augmentin and ciprofloxacin.
• If approved, oral sulopenem could be the first oral penem antibiotic in the U.S., offering a new treatment option for the estimated 40 million uUTIs annually.
• The FDA is expected to complete its review in early Q4 2024, provided the resubmitted NDA addresses prior deficiencies.
Iterum's Oral Sulopenem Shows Superiority in Phase 3 UTI Trial, Stock Upgraded
• Iterum Therapeutics' oral sulopenem demonstrated superiority over Augmentin in a Phase 3 trial for uncomplicated urinary tract infections (uUTI).
• The trial met its primary endpoint with statistical significance, showing a higher overall response rate for sulopenem compared to Augmentin.
• Iterum plans to resubmit a New Drug Application (NDA) in Q2 2024, anticipating FDA approval by Q4 2024.
• H.C. Wainwright upgraded Iterum Therapeutics to a Buy rating with a price target of $6.00 based on the trial's success.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath